Shenzhen Hosts 2022 Biopharmaceutical Industry Innovation Summit to Advance the 'Cell Ecosystem'

The "2022 Biomedical Industry Innovation Summit," jointly hosted by BD and the Shenzhen Biomedical Promotion Association, was held in Shenzhen on August 20. Nearly 200 experts, scholars, leading enterprises, and ecosystem service enterprise representatives gathered to exchange ideas on new trends and advancements in the biomedical industry, promoting collaborative progress across the entire biomedical industry in the Greater Bay Area. The event played a positive role in fostering a multi-disciplinary, innovation-driven "Cell Ecosystem."

Wang Tong, Vice President of Channel and Key Account Management for Greater China at BD, stated: "From research, clinical translation to GMP production, all parts of the industry chain are actively seeking comprehensive solutions with stable standards. As a leading company in the field, BD is committed to providing stable, user-friendly, and efficient comprehensive solutions for various application scenarios in the biopharmaceutical industry."

Zhang Caiwan, Secretary General of Shenzhen Biomedical Promotion Association, stated: "By 2025, the added value of Shenzhen's biomedical industry will reach 40 billion yuan, with operating revenue reaching 100 billion yuan. At the same time, the industrial structure will continue to optimize, and scientific and technological innovation capabilities will significantly improve. This conference has brought together all stakeholders in the region to carry out collaborative innovation and practice, further promoting win-win cooperation and the long-term development of the biomedical industry."

The biopharmaceutical industry has a wide-ranging impact and is bringing profound changes to many fields of people's health and life. Regarding the widely concerned COVID-19 pandemic over the past two years, Professor Hongzhou Lu, President of the Third People's Hospital of Shenzhen and Head of the First Shenzhen Public Health Expert Group for Epidemic Prevention and Control, stated: "We have conducted extensive research on the immune mechanisms of the coronavirus, vaccines, and treatment plans. Practical work such as the development of a universal coronavirus mRNA vaccine is currently underway. We firmly believe that as long as we dynamically adjust our research and prevention strategies according to the evolution of the virus, we will surely safeguard public health and win the battle against the epidemic."

In addition, Wang Mingjun, Executive Dean of Shenzhen Innolife Translational Medicine Research Institute, Li Furong, Director of the Scientific Research and Teaching Department of Shenzhen People's Hospital, Wen Limin, Chief Medical Officer of Molecular Intelligence Bio, Xiang Zheng, Professor at Jinan University Translational Medicine Research Institute, Zhu Li, Associate Researcher at Tongji Medical College of Huazhong University of Science and Technology, Bai Fangrong, Senior Partner of Dehe Han Tong Law Firm, Zang Mingfa, Head of the Biomarker Department at CrownBio, Yang Chengmao, Product Application Specialist at BD, and other experts attended the conference. They delivered insightful presentations on innovative technologies and ecosystem services in the biopharmaceutical industry.

The rapidly developing biopharmaceutical industry requires integrated research and analysis solutions from R&D to clinical applications. As a leader in the industry, BD (Becton, Dickinson and Company) continuously delivers innovative products in the fields of flow cytometry and single-cell multi-omics, providing multi-process solutions to numerous professional clients in the biopharmaceutical sector, including cell therapy companies, CROs, and drug development enterprises, thereby becoming a reliable partner in the biomedical industry.

At this summit, BD exhibited a series of innovative flagship products, including the company's first spectral flow cytometer, the BD FACSymphony A5SE, which creatively integrates the two major technological approaches of classical flow cytometry and spectral flow cytometry, making it a revolutionary and comprehensive achievement in flow cytometry technology; the compact and intelligent cell sorter BD FACS Melody, which is simple, accurate, and fast, used in applications such as antibody screening, cell line development, and immune repertoire research; and the BD Rhapsody platform, currently the only platform that truly achieves simultaneous transcriptome, proteome, immune repertoire, and multiplexed sample studies in a single-cell experiment. The stability, ease of use, and high efficiency of BD's integrated solutions attracted widespread attention and inquiries from biopharmaceutical professionals at the conference.

In addition, a FlowJo data analysis exchange meeting was held during the summit. Senior experts He Junyi and You Lifang from BD Medical shared and discussed in depth on multi-color compensation calculation, efficient basic analysis, and multi-dimensional algorithm interpretation, helping the biopharmaceutical industry improve analysis efficiency, expand data interpretation dimensions, and deepen the depth of data mining. (Zhu Wang)